PT  - JOURNAL ARTICLE
AU  - Nissen, Sara Konstantin
AU  - Farmen, Kristine
AU  - Carstensen, Mikkel
AU  - Schulte, Claudia
AU  - Goldeck, David
AU  - Brockmann, Kathrin
AU  - Romero-Ramos, Marina
TI  - Dynamic changes in the CD163+ and CCR2+ peripheral monocytes during Parkinson’s disease
AID  - 10.1101/2021.03.15.21253572
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.15.21253572
4099  - http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253572.short
4100  - http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253572.full
AB  - Background Alpha-synuclein aggregates and accumulation are associated with immune activation and neurodegeneration in Parkinson’s disease. The immune activation is not only dependent on the brain-resident microglial cells but also involves peripheral immune cells, such as mononuclear phagocytes including monocytes and dendritic cells, found in the blood as well as infiltrated into the brain. Understanding the involvement of the peripheral immune component in Parkinson’s disease is essential for the development of immunomodulatory treatment, which might modify disease progression. We aimed to study the profile of circulating mononuclear phagocytes in early- and late-stage Parkinson’s disease by analyzing surface-expressed molecules related to phagocytosis, alpha-synuclein sensing, and tissue-migration.Methods Multi-color flow cytometry on peripheral mononuclear cells from cross-sectional samples of 80 gender-balance individuals with early- and late-stage sporadic Parkinson’s disease, and 29 controls, as well as longitudinal samples from seven patients and one control. Cells were delineated into natural killer cells, monocyte subtypes, and dendritic cells with cell frequencies and surface marker expressions compared between patients and controls, and correlated with standardized clinical motor and non-motor scores.Results Overall, we found elevated frequencies and surface levels of markers related to migration (CCR2, CD11b) and phagocytosis (CD163) particularly on the elevated classical and intermediate monocytes in patients with Parkinson’s disease for less than five years. This corresponded to a decrease of non-classical monocytes and dendritic cells. We observed an increased HLA-DR expression late in disease and sexual-dimorphism with TLR-4 expression decreased in women with PD but not in males. The disease-associated immune changes on TLR4, CCR2, and CD11b were correlated with non-motor symptoms such as olfaction or cognition. While many alterations were normalized at late disease stage, other changes remained, such as the increased HLA-DR and CD163 expressions.Conclusions Our data highlight a role for peripheral CD163+ and migration-competent classical monocytes in Parkinson’s disease. The study further suggests that the peripheral immune system is dynamically altered in Parkinson’s disease stages and directly related to both non-motor symptoms and the sex-bias of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding support for the research covered by this article was provided by the Michael J. Fox Foundation (MRR), the Bjarne Saxhof Fund administered through the Danish Parkinson's Foundation (MRR) and the Danish Council for Independent Research (MRR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the University of Tuebingen (Germany) committee (480/2015BO2).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the conclusions are included within the article and its additional file.(α-syn)alpha-synuclein(BDI-II)Beck Depression Inventory(cDC1)conventional DC type 1(cDC2)conventional DC type 2(cMo)classical monocyte(CNS)central nervous system(DC)dendritic cell(HC)healthy control(iMo)intermediate monocyte(LEDD)Levodopa equivalent daily dosage(MoCA)Montreal Cognitive Assessment(MFI)median fluorescence intensity(MNP)peripheral mononuclear phagocyte(Mo)monocytes(ncMo)macrophage (Mϕ, non-classical monocyte(NK)natural killer(PBMCs)Peripheral blood mononuclear cells(pDCs)plasmacytoid(PD)Parkinson’s disease(PwP)people with PD(REML)repeated-measures mixed-effect model(TLR)toll-like receptor(tSNE)t-distributed stochastic neighbor embedding